Skip to main
  1. Stocks
  2. Lyell Immunopharma
  3. Forecast
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma is attractive because ronde-cel has shown differentiated efficacy in LBCL, with a 77% complete response rate, 91% ORR, and estimated 12-month PFS of 63%, while safety remains favorable with no Grade ≥3 CRS in the reported PiNACLE patients and only 9% Grade ≥3 ICANS. Its commercial case is strengthened by the possibility that roughly half of LBCL CAR-T collections could qualify for a 3L+ label, supported by 98% manufacturing success, a 16-day median vein-to-site time, and a LyFE platform expected to support more than 3,000 doses annually. Financially, the recent $80M financing extends expected cash runway into 2028, giving the company time to reach the planned 2H27 BLA submission and to advance LYL273 as an additional value driver in mCRC and other GCC-expressing cancers.

Bears say

Lyell Immunopharma is a high-risk, pre-commercial cell therapy developer whose outlook is weighed down by meaningful clinical, regulatory, and financing uncertainty across its CAR-T pipeline. The bear case assumes safety issues or regulatory headwinds could delay filings and reduce the probability of success for ronde-cel to 15% in DLBCL and LYL273 to 5%, while LYL273’s CARABINer updates and End-of-Phase I FDA meeting were pushed to 2027 from 2H:26. With no FDA or EMA approvals, intense competition in LBCL and mCRC, likely reimbursement pressure, and a need for additional funding that may not be available on favorable terms, execution risk remains elevated.

Lyell Immunopharma (LYEL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction

Get the latest Lyell Immunopharma (LYEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lyell Immunopharma (LYEL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction

Get the latest Lyell Immunopharma (LYEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Lyell Immunopharma (LYEL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LYEL stock data and trends